This article is more than 5 years old. Information may no longer be current.

Fresenius Medical Care North America aims to move more dialysis patients to Mircera

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Fresenius Medical Care North America aims to have 110,000 of its dialysis patients, or 71%, using Roche's drug Mircera instead of Amgen's Epogen by the end of the first quarter of 2016, the company's CEO Rice Powell said during an investor call. Powell said about 155,000 of the company's 180,000 dialysis patients require regular treatment with an erythropoietin-stimulating agent.

At the end of the fourth quarter of 2015, Powell said 95,000 of their patients had received multiple doses of Mircera.

When asked if it's possible that the company could have as many as 135,000 patients taking Mircera in the long term, Powell said " I don't think it's out of the realm of possibility that we could be up around the 135,000 patients, but it's hard for me to predict because there's just a lot of different variables that go into that."